scholarly journals Clinical efficacy of subcutaneous and sublingual allergen-specific immunotherapy of allergic rhinitis and conjunctivitis

2016 ◽  
Vol 13 (6) ◽  
pp. 63-69
Author(s):  
I E Kozulina ◽  
K S Pavlova ◽  
O M Kurbacheva
Keyword(s):  
Allergic Rhinitis ◽  
Pollen Season ◽  
Specific Immunotherapy ◽  
Pharmacoeconomic Analysis ◽  
Birch Pollen ◽  
Cost Utility ◽  
Efficacy And Safety ◽  
Allergen Specific Immunotherapy ◽  
Cost Efficacy ◽  
The Cost

Objective. To evaluate the efficacy and safety of subcutaneous and sublingual allergen-specific immunotherapy (AIT), a comparative pharmaco-economic analysis. Materials and methods. The study included 60 patients with allergic rhinitis and conjunctivitis with or without asthma induced by birch pollen. In the first group patients received subcutaneous AIT (SCIT) by «Phostal - allergen of trees pollen», in the second group - sublingual AIT (SLIT) by «Staloral - allergen of birch pollen». Results. All patients after the SCIT or SLIT in the first pollen season noted a decrease in the severity of nasal and conjunctival symptoms (SMD -1,93 [95% CI -2,39; -1,47] and -1,57 [95% CI -2,39; -0,75] for groups 1 and 2, respectively) and a decrease in the rescue medication requirement (SMD -1,98 [95% CI -2,57; -1,39] and -1,86 [95% CI -2,61; -1,11] for groups 1 and 2, respectively). There were no statistically significant differences between the SCIT and SLIT efficacy. After AIT in both groups there was a significant reduction in the cost of medication and medical services (on average 5 times). In a comparative pharmacoeconomic analysis «cost/efficacy» and «cost/utility» was showed comparable results of SCIT and SLIT.

scholarly journals Pollen allergy and household budget

2011 ◽  
Vol 8 (4) ◽  
pp. 79-83
Author(s):  
M A Mokronosova ◽  
M A Mokronosova
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Specific Immunotherapy ◽  
Birch Pollen ◽  
Pollen Allergy ◽  
Direct Costs ◽  
Middle Part ◽  
Allergen Specific Immunotherapy ◽  
Severity Of The Disease

The prevalence of the allergy to birch pollen is high in the middle part of russian Federation. the symptoms of allergic intermittent rhinitis appears in the first decade and lasted during all life. the severity of the disease is aggravated annually. the economic burden of allergic rhinitis includes direct, indirect and hidden costs. the indirect cost (disability and loss of productivity, hypoallergenic life arrangements) exceeds direct costs many times. allergen specific immunotherapy by pollen allergovaccines is unique kind of pathogenic management. asIt demonstrates significant improvement of the symptoms of rhinitis and asthma, quality of life. one of the main problems is high costs of asIt. economical models used in investigations on asIt cost effectiveness demonstrated lucre in the following 10 years of life after 3 year's course of asIt. In order to achieve high clinical result it is necessary to follow european standard's guidance on specific immunotherapy strictly.

Pharmacoeconomic analysis of bronchial asthma prophylaxis in adults and children with allergic rhinitis with sublingual allergen-specific immunotherapy

2021 ◽  
Author(s):  
Valeriya A Lemeshko ◽  
Svetlana S Ratushnyak ◽  
Filipp V Gorkavenko ◽  
Evgeniya V Nazarova ◽  
Natalia I Ilina ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Cost Benefit Analysis ◽  
Therapy Group ◽  
Pharmacoeconomic Analysis ◽  
Cost Benefit ◽  
Symptomatic Therapy ◽  
Tree Model ◽  
Allergen Specific Immunotherapy ◽  
The Cost

AIMS: to evaluate the cost-effectiveness of sASIT in children and adult patients with allergic rhinitis and / or allergic rhinoconjunctivitis. MATERIALS AND METHODS: the hypothesis of the study was based on results of the study by Devillier P. et al., 2019, according to which the incidence of asthma was 13.7% and 17.0% in the sASIT + symptomatic therapy groups and the symptomatic therapy group (odds ratio - 0.776, 95% confidence interval (0.622; 0.968)). Pharmacoeconomic study based on decision tree model. Costs taken into account: cost of sASIT, symptomatic therapy, diagnostics and routine follow-up visits due to BA, outpatient BA drug therapy, the cost of hospitalization due to BA. The modeling horizon was 5 years, including 2 years of sASIT therapy and 3 years of follow-up. RESULTS: the cost per patient when using sASIT in combination with symptomatic therapy was 166,711.93 rubles, with symptomatic therapy - 101,700.35 rubles. The CER for sASIT in combination with symptomatic therapy was 193,177.20 rubles. per 1 prevented case of asthma, for symptomatic therapy - 122,530.55 rubles. for 1 prevented case of BA. Thus, the cost of 1 averted AB case when using sASIT in combination with symptomatic therapy is 57.7% higher than with symptomatic therapy. According to the results of the cost-benefit analysis, ICUR for an additional year of life adjusted for its quality (QALY) when performing sASIT in combination with symptomatic therapy compared with symptomatic therapy alone in children and adults was 567,365.48 rubles, which is less than calculated willingness to pay threshold (WTPT) (RUB 2,248,898.50). CONCLUSIONS: based on the results of comparing the cost of 1 added QALY and WTPT, it can be concluded that sASIT in combination with symptomatic therapy compared to symptomatic therapy alone is potentially cost-effective in children and adults with AR.

Effects of allergen-specific immunotherapy on functions of helper and regulatory T cells in patients with seasonal allergic rhinitis

2011 ◽  
Vol 22 (1) ◽  
pp. 15-23 ◽  
Author(s):  
Cengiz Kirmaz ◽  
Ozlem Ozenturk Kirgiz ◽  
Papatya Bayrak ◽  
Ozge Yilmaz ◽  
Seda Vatansever ◽  
...  
Keyword(s):  
T Cells ◽  
Allergic Rhinitis ◽  
Regulatory T Cells ◽  
Seasonal Allergic Rhinitis ◽  
Specific Immunotherapy ◽  
Allergen Specific Immunotherapy

Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis

2017 ◽  
Vol 131 (11) ◽  
pp. 997-1001 ◽  
Author(s):  
E Sahin ◽  
D Dizdar ◽  
M E Dinc ◽  
A A Cirik
Keyword(s):  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Specific Immunotherapy ◽  
Subcutaneous Immunotherapy ◽  
Long Term Effects ◽  
Allergen Specific Immunotherapy ◽  
Dust Mite ◽  
Symptom Scores

AbstractBackground:Allergic rhinitis is strongly associated with the presence of house dust mites. This study investigated the long-term effects of allergen-specific immunotherapy. Allergen-specific immunotherapy was applied over three years. The study was based on a 10-year follow up of patients with allergic rhinitis.Methods:The study was conducted between 2001 and 2015. Skin prick test results and symptom scores were evaluated before (26 patients) and after 3 years (20 patients) of allergen-specific immunotherapy (using data from a previously published study), and 10 years after allergen-specific immunotherapy had ended (20 of 26 patients).Results:The symptom scores before allergen-specific immunotherapy were significantly higher than those obtained after 3 years of allergen-specific immunotherapy and 10 years after allergen-specific immunotherapy (p < 0.0175). There were no significant differences between the scores obtained at 3 years and 10 years after allergen-specific immunotherapy (p > 0.0175).Conclusion:Subcutaneous immunotherapy is an effective treatment for house dust mite induced allergic rhinitis.

GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma

Allergy ◽  
2010 ◽  
Vol 65 (12) ◽  
pp. 1525-1530 ◽  
Author(s):  
T. Zuberbier ◽  
C. Bachert ◽  
P. J. Bousquet ◽  
G. Passalacqua ◽  
G. Walter Canonica ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Specific Immunotherapy ◽  
Allergen Specific Immunotherapy

scholarly journals Specific probiotics alleviate allergic rhinitis during the birch pollen season

2009 ◽  
Vol 15 (26) ◽  
pp. 3261 ◽  
Author(s):  
Arthur C Ouwehand ◽  
Merja Nermes ◽  
Maria Carmen Collado ◽  
Nina Rautonen ◽  
Seppo Salminen ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Pollen Season ◽  
Birch Pollen
Sign in / Sign up

Export Citation Format

Share Document